Knopman DS, Jack Jr CR, Wiste HJ, et al. Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology. 2016;87:691–8.
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15. e11-14.
Scholl M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971–82.
Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.
Sanchez-Juan P, Ghosh PM, Hagen J, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82:230–8.
Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs213.
Mungas D, Tractenberg R, Schneider JA, et al. A 2-process model for neuropathology of Alzheimer’s disease. Neurobiol Aging. 2014;35:301–8.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.
•• Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces abeta plaques in Alzheimer’s disease. Nature. 2016;537:50–6. The first report accomplishing amyloid removal from the brain of patients with mild cognitive impairment due to AD and an associated improvement in some cognitive scores.
Zhang X, Jin H, Padakanti PK, et al. Radiosynthesis and in vivo evaluation of two PET radioligands for imaging alpha-synuclein. Appl Sci (Basel). 2014;4:66–78.
ALS Association (2016) ALS find a cure. http://www.alsa.org/news/media/press-releases/grand-challenge-generation-020816.html.
Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.
Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67.
Yau WY, Tudorascu DL, McDade EM, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2015;14:804–13.
• Petersen RC, Wiste HJ, Weigand SD, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73:85–92. This is a large longitudinal study in healthy elderly at the Mayo Clinic showing how a positive abeta PET study increases the risk of developing cognitive impairment.
• Burnham SC, Bourgeat P, Dore V, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016;15:1044–53. This is a large longitudinal study in healthy elderly at Melbourne showing how a positive abeta PET study increases the risk of developing cognitive impairment.
Jack Jr CR, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47.
Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957–65.
Su Y, Blazey TM, Owen CJ, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer’s disease: results from the DIAN study group. PLoS One. 2016;11, e0152082.
Mosconi L, Rinne JO, Tsui WH, et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer’s parents. Neurobiol Aging. 2013;34:22–34.
Orban P, Madjar C, Savard M, et al. Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease. Sci Data. 2015;2:150043.
Bron EE, Steketee RM, Houston GC, et al. Diagnostic classification of arterial spin labeling and structural MRI in presenile early stage dementia. Hum Brain Mapp. 2014;35:4916–31.
Andrews KA, Frost C, Modat M, et al. Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiol Aging. 2016;39:99–107.
• Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452–8. Recent genetic data implying inflammation-related gene variants as risk factors for Alzheimer’s disease.
•• Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27. Recent genetic data implying inflammation-related gene variants as risk factors for Alzheimer’s disease.
• Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848–50. Recent genetic data implying inflammation-related gene variants as risk factors for Alzheimer’s disease.
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020–33.
Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain. 2015;138:1370–81.
Choi SR, Schneider JA, Bennett DA, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26:8–16.
Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398–403.
Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement. 2015;11:964–72.
• Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240–9. This study shows the good correlation between abeta CSF and abeta PET in the early stages of the AD process.
Jack Jr CR, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131:665–80.
Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92.
Chetelat G, Villemagne VL, Pike KE, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer’s disease. Neurodegener Dis. 2012;10:141–4.
Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70:857–61.
Lim YY, Laws SM, Villemagne VL, et al. Abeta-related memory decline in APOE epsilon4 noncarriers: implications for Alzheimer disease. Neurology. 2016;86:1635–42.
Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol. 2012;69:623–9.
Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of intellectual enrichment on AD biomarker trajectories: longitudinal imaging study. Neurology. 2016;86:1128–35.
Brown BM, Rainey-Smith SR, Villemagne VL, et al. The relationship between sleep quality and brain amyloid burden. Sleep. 2016;39:1063–8.
Schreiber S, Landau SM, Fero A, et al. Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. JAMA Neurol. 2015;72:1183–90.
Kantarci K, Lowe V, Przybelski SA, et al. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology. 2012;78:232–40.
Lim YY, Villemagne VL, Laws SM, et al. BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiol Aging. 2013;34:2457–64.
Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034–42.
Serrano GE, Sabbagh MN, Sue LI, et al. Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis. 2014;42:813–21.
Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013;9:438–44.
Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to alzheimer’s disease in the community. Ann Neurol. 2013;74:199–208.
Mathis CA, Kuller LH, Klunk WE, et al. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann Neurol. 2013;73:751–61.
Monsell SE, Mock C, Roe CM, et al. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2013;80:2121–9.
Nelson PT, Head E, Schmitt FA, et al. Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121:571–87.
Perez-Nievas BG, Stein TD, Tai HC, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain. 2013;136:2510–26.
Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241–9.
Shin J, Kepe V, Barrio JR, et al. The merits of FDDNP-PET imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26:135–45.
Jonasson M, Wall A, Chiotis K, et al. Tracer kinetic analysis of (S)-(1)(8)F-THK5117 as a PET tracer for assessing tau pathology. J Nucl Med. 2016;57:574–81.
Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68.
Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108.
Villemagne VL, Fodero-Tavoletti MT, Masters CL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114–24.
Chiotis K, Saint-Aubert L, Savitcheva I, et al. Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016;43:1686–99.
Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–14.
Pascual B, Masdeu JC. Tau, amyloid, and hypometabolism in the logopenic variant of primary progressive aphasia. Neurology. 2016;86:487–8.
Pascual B, Rockers E, Bajaj S, et al. Older healthy people have increased vascular permeability in regions showing “off-target” [18F]AV-1451 uptake. Alzheimer Assoc Int Conf. 2016;Abstract a9714.
Ikonomovic MD, Abrahamson EE, Price JC, et al. [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than “off-target” binding. Ann Neurol. 2016;80:307–8.
Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787–800.
Hansen AK, Knudsen K, Lillethorup TP, et al. In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain. 2016;139:2039–49.
• Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67. This is an early study showing a good correlation between the topography of tau deposition in vivo and the clinical phenotype.
Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4:58. doi:10.1186/s40478-016-0315-6.
Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. 2016. doi:10.1002/mds.26813.
Josephs KA, Whitwell JL, Tacik P, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016; (in press, on line)
Taniguchi-Watanabe S, Arai T, Kametani F, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267–80.
Smith R, Puschmann A, Scholl M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139:2372–9.
Wang L, Benzinger TL, Su Y, et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy. JAMA Neurol. 2016;73:1070–7.
Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362–81.
Finnema SJ, Nabulsi NB, Eid T, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8:348ra396.
O’Brien JT, Firbank MJ, Davison C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med. 2014;55:1959–65.
Herholz K. Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging. 2014;58:332–43.
Chen K, Ayutyanont N, Langbaum JB, et al. Characterizing Alzheimer’s disease using a hypometabolic convergence index. Neuroimage. 2011;56:52–60.
Bozoki, AC, Korolev, IO, Davis, NC, et al. Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer’s disease: A DTI/FDG-PET Study. Hum Brain Mapp. 2011
Drzezga A, Becker JA, Van Dijk KR, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635–46.
Caroli A, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012;53:592–600.
Wong CY, Thie J, Gaskill M, et al. A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging. BMC Nucl Med. 2006;6:4.
Chen Y, Wolk DA, Reddin JS, et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology. 2011;77:1977–85.
Buchbinder BR. Functional magnetic resonance imaging. Handb Clin Neurol. 2016;135:61–92.
Power JD, Barnes KA, Snyder AZ, et al. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012;59:2142–54.
Jacobs HI, Van Boxtel MP, Heinecke A, et al. Functional integration of parietal lobe activity in early Alzheimer disease. Neurology. 2012;78:352–60.
Bondi MW, Houston WS, Eyler LT, et al. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005;64:501–8.
Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med. 2000;343:450–6.
Trivedi MA, Schmitz TW, Ries ML, et al. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer’s disease. Neuropsychologia. 2008;46:1667–78.
Mondadori CR, de Quervain DJ, Buchmann A, et al. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex. 2007;17:1934–47.
Nichols LM, Masdeu JC, Mattay VS, et al. Interactive effect of apolipoprotein E genotype and age on hippocampal activation during memory processing in healthy adults. Arch Gen Psychiatry. 2012;69:804–13.
Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27–35.
O’Brien JL, O’Keefe KM, LaViolette PS, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969–76.
Masdeu J, Aronson M. CT findings in early dementia. The Gerontologist. 1985;25:82.
Jack Jr CR, Knopman DS, Chetelat G, et al. Suspected non-Alzheimer disease pathophysiology—concept and controversy. Nat Rev Neurol. 2016;12:117–24.
Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804.
Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048–56.
Apostolova LG, Hwang KS, Medina LD, et al. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;32:118–25.
Caroli A, Prestia A, Galluzzi S, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology. 2015;84:508–15.
Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1:13–21.
Kloppel S, Stonnington CM, Barnes J, et al. Accuracy of dementia diagnosis: a direct comparison between radiologists and a computerized method. Brain. 2008;131:2969–74.
Wolz R, Julkunen V, Koikkalainen J, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer’s disease. PLoS One. 2011;6:e25446.
Hua X, Leow AD, Parikshak N, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43:458–69.
Heister D, Brewer JB, Magda S, et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011;77:1619–28.
Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. Lancet Neurol. 2012;11:868–77.
Ringman JM, O’Neill J, Geschwind D, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain. 2007;130:1767–76.
Smith CD, Chebrolu H, Andersen AH, et al. White matter diffusion alterations in normal women at risk of Alzheimer’s disease. Neurobiol Aging. 2010;31:1122–31.
Fortea J, Sala-Llonch R, Bartres-Faz D, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis. 2010;22:909–22.
Kim WH, Adluru N, Chung MK, et al. Multi-resolution statistical analysis of brain connectivity graphs in preclinical Alzheimer’s disease. Neuroimage. 2015;118:103–17.
Douaud G, Jbabdi S, Behrens TE, et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer’s disease. Neuroimage. 2011;55:880–90.
Wee CY, Yap PT, Zhang D, et al. Identification of MCI individuals using structural and functional connectivity networks. Neuroimage. 2012;59:2045–56.
O’Dwyer L, Lamberton F, Bokde AL, et al. Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PLoS One. 2012;7, e32441.
Ferretti MT, Cuello AC. Does a pro-Inflammatory process precede Alzheimer’s disease and mild cognitive impairment? Curr Alzheimer Res. 2011;8:164–74.
Serrano-Pozo A, Mielke ML, Gomez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol. 2011;179:1373–84.
Hoozemans JJ, Rozemuller AJ, van Haastert ES, et al. Neuroinflammation in Alzheimer’s disease wanes with age. J Neuroinflammation. 2011;8:171.
Maeda J, Zhang MR, Okauchi T, et al. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. J Neurosci. 2011;31:4720–30.
Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56–62.
Kreisl WC, Fujita M, Fujimura Y, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage. 2010;49:2924–32.
Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–7.
Schuitemaker A, Kropholler MA, Boellaard R, et al. Microglial activation in Alzheimer’s disease: an (R)-[(1)(1)C]PK11195 positron emission tomography study. Neurobiol Aging. 2013;34:128–36.
Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an 11C (R)PK11195-PET and 11C PIB-PET study. Neurobiol Dis. 2008;32:412–9.
Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain. 2013;136:2228–38.
Lyoo CH, Ikawa M, Liow JS, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. 2015;56:701–6.
Carter SF, Scholl M, Almkvist O, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37–46.
Brun A, Englund E. Regional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading. Histopathology. 1981;5:549–64.
Pascual B, Prieto E, Arbizu J, et al. Decreased carbon-11-flumazenil binding in early Alzheimer’s disease. Brain. 2012;135:2817–25.
Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497–510.
Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42–52.
Spinelli EG, Agosta F, Ferraro PM, et al. Brain MR imaging in patients with lower motor neuron-predominant disease. Radiology. 2016;280:545–56.
Lehmann M, Madison CM, Ghosh PM, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013;110:11606–11.
Zhou J, Gennatas ED, Kramer JH, et al. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216–27.
Sepulcre J, Schultz AP, Sabuncu M, et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J Neurosci. 2016;36:7364–74.
Sepulcre J, Masdeu JC. Advanced neuroimaging methods towards characterization of early stages of AD. In: Castrillo JI, Oliver SG, editors. Systems Biology of Alzheimer’s Disease. London: Humana Press; 2015.
Hebb DO. Distinctive features of learning in the higher animal. In: Delafresnaye JF, editor. Brain Mechanisms and Learning. London: Oxford University Press; 1961. p. 37–46.
Sepulcre J, Sabuncu MR, Johnson KA. Network assemblies in the functional brain. Curr Opin Neurol. 2012;25:384–91.
de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron. 2012;73:685–97.
Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7, e31302.
Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949–53.
Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013;47:601–23.
Franklin BS, Bossaller L, De Nardo D, et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol. 2014;15:727–37.
Rowe CC, Pejoska S, Mulligan RS, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880–6.
Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398–407.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4